MindBio Issues Restricted Stock Units

MindBio Therapeutics Corp. has issued Restricted Stock Units (RSUs) to certain directors and individuals working for the company.

The company's Board of Directors approved the issuance of 8,000,000 RSUs to two independent directors and 27,004,730 RSUs to twelve staff and contractors in lieu of cash compensation. The RSUs vest upon the occurrence of a "Vesting Event," with one share issued for each vested RSU.

According to Justin Hanka, CEO, securing talented people is crucial for the company's success as it enters its next stage of clinical trials. He added that the issuing of RSUs aligns the interests of the individuals and the company's shareholders.

MindBio is focused on developing novel psychedelic-based medicines for mental health disorders and is pioneering the use of regulated, take-home use of psychedelic medicines in clinical trials to provide treatments for conditions such as depression, anxiety, and other psychological challenges.

MindBio aims to redefine mental health treatment by scaling the regulated take-home use of psychedelic medicines in advanced clinical trials, prioritizing accessibility and affordability.

MindBio invites stakeholders to support its vision for a brighter future in mental health.

MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia.